Vivitrol (Extended-Release Injectable Naltrexone) for Alcohol Use Disorder

A Comprehensive Guide for Patients, Clinicians, and Program Administrators

A note on this article's evidence base: This article was developed following a structured expert panel review. The panel — comprising an addiction medicine physician, clinical pharmacist, criminal justice/reentry specialist, primary care implementation researcher, and patient advocate — conducted a rigorous gap analysis of the available document corpus. The panel's central finding was that the corpus provided to them contained no retrievable documents on this topic, and they unanimously declined to fabricate citations. The clinical content in this article draws on established pharmacological knowledge and publicly available regulatory information about Vivitrol. Where specific citations would normally appear, this article notes the evidence type and source category honestly. Readers — especially clinicians and program administrators — should consult primary sources including the FDA-approved prescribing information, ASAM guidelines, and peer-reviewed publications before making treatment decisions.

Overview

Vivitrol is the brand name for extended-release naltrexone (XR-NTX), delivered as a 380mg intramuscular injection given once a month. It is the same active medication as oral naltrexone tablets — the difference is entirely in how it is delivered and how long it stays active in the body.

The FDA approved Vivitrol for alcohol use disorder (AUD) in 2006 and for opioid use disorder (OUD) in 2010. This article focuses on its use in AUD.

When people search for this medication, they use many different terms: Vivitrol, extended-release naltrexone, XR naltrexone, depot naltrexone, naltrexone injection, and Vivitrol shot all refer to the same treatment. Understanding that these terms are interchangeable helps patients and clinicians find consistent information.

The core clinical rationale for Vivitrol over oral naltrexone is straightforward: one injection per month instead of one pill every day. For people whose recovery is disrupted by the daily decision to take a pill — or by simply forgetting — that difference can be clinically significant.

How Vivitrol Differs from Oral Naltrexone

Oral naltrexone is a 50mg tablet taken daily. Vivitrol is a 380mg extended-release injectable suspension administered intramuscularly once every four weeks. Both medications contain naltrexone and work through the same mechanism. The differences are in delivery, pharmacokinetics, adherence profile, and cost.

Pharmacokinetics: Oral naltrexone is absorbed through the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver before reaching systemic circulation. This means plasma levels fluctuate significantly — peaking after each dose and falling before the next. Vivitrol uses a microsphere depot technology: tiny polymer spheres containing naltrexone are injected into the gluteal muscle, where they slowly release the medication over approximately 28 days. This bypasses first-pass metabolism and produces more stable, sustained plasma concentrations throughout the dosing interval. The result is consistent mu-opioid receptor blockade without the peaks and troughs associated with daily dosing.

Adherence: This is the primary clinical argument for Vivitrol. Daily pill adherence in AUD treatment is a well-documented challenge. A person who misses several days of oral naltrexone loses its protective effect precisely during the period when they may be most vulnerable. With Vivitrol, once the injection is administered, the medication is working for the full month regardless of what the patient does or doesn't do each morning. The adherence advantage is structural, not motivational.

Cost: Vivitrol costs approximately $1,500 per monthly dose at wholesale. Oral naltrexone costs approximately $30 per month in generic form. This is not a minor difference. The cost gap is the primary reason oral naltrexone remains the appropriate first-line choice for many patients, and it is a reason that must be discussed honestly with every person considering Vivitrol.

Formulation: Oral naltrexone can be started, stopped, or dose-adjusted easily. Vivitrol, once injected, cannot be removed. If a patient experiences a serious adverse reaction, the medication cannot be reversed or withdrawn. This irreversibility is a meaningful clinical consideration, particularly for patients new to naltrexone.

Mechanism: How Vivitrol Works

Naltrexone is a mu-opioid receptor antagonist. It binds to opioid receptors in the brain and blocks them — without activating them. This is fundamentally different from medications like methadone or buprenorphine, which activate opioid receptors (agonist or partial agonist effects).

In the context of alcohol use disorder, the mechanism works through the brain's endogenous opioid system. Alcohol consumption triggers the release of endorphins, which bind to opioid receptors and contribute to the pleasurable, rewarding effects of drinking. Naltrexone blocks those receptors, reducing the reward signal that alcohol produces. Over time, this blunts the craving for alcohol and reduces the reinforcing effect of drinking — making it easier for people to drink less or stop entirely.

Vivitrol does not make a person feel sick when they drink alcohol (that is disulfiram/Antabuse). It does not produce sedation or euphoria. It does not cause physical dependence. In a person who is not opioid-dependent, it produces no noticeable effect at rest — its action becomes apparent primarily when alcohol or opioids are consumed.

Important: In a person who is currently opioid-dependent, naltrexone will precipitate immediate, severe withdrawal. This is why the opioid washout requirement described in the next section is the single most critical safety point in Vivitrol prescribing.

Trial Evidence

The foundational efficacy evidence for Vivitrol in AUD comes from several key sources that any complete clinical corpus on this topic must include.

The Garbutt 2005 Pivotal Trial: The pivotal randomized controlled trial supporting Vivitrol's FDA approval for AUD was published by Garbutt and colleagues in 2005. This trial demonstrated that patients receiving the 380mg monthly injection had significantly fewer heavy drinking days compared to placebo, establishing the core efficacy signal that led to FDA approval. This is the single most important document for understanding Vivitrol's evidence base in AUD.

The COMBINE Study: The COMBINE study (Anton et al., JAMA, 2006) is the foundational efficacy anchor for naltrexone in AUD more broadly. While it primarily examined oral naltrexone, it provides the comparative framework within which Vivitrol's effects are understood. The COMBINE study tested naltrexone against placebo and against behavioral interventions, establishing that naltrexone — with or without intensive behavioral therapy — reduces heavy drinking days and increases abstinence rates. Any responsible discussion of Vivitrol's place in AUD treatment must be grounded in this evidence.

Meta-analytic evidence: Systematic reviews of naltrexone for AUD have consistently found meaningful reductions in heavy drinking episodes compared to placebo. The expert panel that reviewed this topic identified a meta-analytic risk ratio in the range of 0.69 for heavy drinking with naltrexone versus placebo — a figure consistent with the published literature — but was unable to verify this specific figure against a corpus document during their review. Clinicians should consult current Cochrane reviews and ASAM guidelines for the most current pooled estimates.

Real-world VA studies: Studies from the Veterans Affairs healthcare system have examined naltrexone adherence in real-world populations and generally support the adherence advantage of extended-release formulations over daily oral dosing, particularly in patients with documented non-adherence to oral therapy.

What the evidence shows overall: Vivitrol produces clinically meaningful reductions in heavy drinking days and increases in abstinence days compared to placebo. Effect sizes are generally similar to oral naltrexone in head-to-head comparisons, with the real-world advantage of Vivitrol appearing primarily in populations where daily adherence is a documented barrier. Vivitrol is not a cure for AUD and works best as part of a comprehensive treatment plan that includes counseling and support.

The Opioid Washout Requirement

This is the single most important safety point in Vivitrol prescribing. Read this section carefully.

Before a person receives their first Vivitrol injection — or any injection after a gap during which opioid use may have occurred — they must be completely free of opioids for a minimum of 7 to 10 days for short-acting opioids (heroin, oxycodone, hydrocodone, morphine). For long-acting opioids, the washout period is longer:

• Methadone: Minimum 10–14 days, often longer depending on dose
• Buprenorphine (Suboxone, Subutex): Minimum 7–10 days after the last dose
• Extended-release opioid formulations: Consult prescribing information for specific washout guidance

Why this matters: Naltrexone has extremely high affinity for opioid receptors — higher than most opioids themselves. If opioids are still present in the body when naltrexone is administered, naltrexone will displace them from receptors and trigger precipitated withdrawal. Precipitated withdrawal is not the same as ordinary opioid withdrawal. It is sudden, severe, and can begin within minutes of the injection. Symptoms include intense nausea and vomiting, severe abdominal cramping, profuse sweating, agitation, and extreme discomfort. Unlike ordinary withdrawal, it cannot be managed by simply taking an opioid — the naltrexone blocks those receptors for weeks.

Clinical protocol before injection:
1. Conduct a thorough opioid use history, including prescribed and non-prescribed opioids
2. Obtain a urine drug screen (UDS) — note that buprenorphine requires specific UDS panels
3. Perform a clinical assessment for signs of opioid withdrawal or intoxication
4. Consider a naloxone challenge test if opioid use history is uncertain
5. Document that the patient is opioid-free and clinically appropriate for injection

The washout window is where patients are lost. As the addiction medicine expert on the panel noted, the gap between "patient agrees to treatment" and "patient receives treatment" can become a chasm during the washout period. Patients who are opioid-dependent must complete medically supervised withdrawal before Vivitrol can begin — and that process requires support, monitoring, and often bridge medications. Programs that do not have a structured washout protocol will see high dropout rates before the first injection is ever given.

Injection Technique and Site

Vivitrol is not a standard intramuscular injection. It requires specific preparation and technique.

Preparation: Vivitrol comes as a powder that must be reconstituted with the supplied diluent immediately before administration. The reconstitution process involves specific steps that must be followed precisely — errors in preparation can result in incorrect dosing or device failure. The medication should be allowed to reach room temperature before injection if it has been refrigerated.

Storage: Vivitrol requires refrigeration (2°C to 8°C / 36°F to 46°F). It can be stored at room temperature (up to 25°C / 77°F) for no more than 7 days before use. Cold-chain management from distributor to point of administration is a real operational consideration for clinics and programs.

Administration site: Vivitrol is administered as a deep intramuscular injection into the gluteal muscle — not the deltoid, not subcutaneous tissue. A 2-inch needle is typically required to ensure proper depth, particularly in patients with higher body mass. Subcutaneous injection (too shallow) significantly increases the risk of injection site reactions and may compromise absorption.

Site rotation: Injection sites should be alternated between the left and right gluteal muscles with each monthly dose. This reduces the risk of tissue damage and nodule formation at any single site.

Who administers it: Vivitrol must be administered by a healthcare professional. It cannot be self-administered. This is both a safety requirement and a logistical consideration for program design — patients must come to a clinic or office monthly.

Common injection site reactions: Pain, tenderness, induration (hardening), and bruising at the injection site are common and typically resolve within a few weeks. Nodule formation can occur. Rare but serious injection site reactions — including necrosis requiring surgical management — have been reported and are described in the prescribing information. Patients should be instructed to report any injection site changes that worsen rather than improve over time.

Side Effects

Most common side effects:
- Injection site reactions (pain, induration, nodule) — the most frequently reported
- Nausea — particularly in the first few days after injection
- Headache
- Fatigue
- Decreased appetite
- Dizziness

Hepatotoxicity warning: Naltrexone carries a black box warning for hepatotoxicity at high doses. At the doses used clinically for AUD and OUD, serious liver injury is rare, but liver function tests (LFTs) should be monitored, particularly in patients with pre-existing liver disease. Vivitrol is not recommended in patients with acute hepatitis or liver failure.

Depression and suicidality: Cases of depression, including suicidal ideation, have been reported in patients receiving naltrexone. The causal relationship is not fully established, but patients should be monitored for mood changes, particularly in the weeks following injection. Patients with a history of depression or suicidality warrant closer follow-up.

Opioid pain management: Because Vivitrol blocks opioid receptors, standard opioid pain medications will not work effectively while the medication is active. This is a critical consideration for surgical planning and emergency pain management. Patients should carry a medical alert card indicating they are receiving naltrexone. In emergency situations, higher doses of opioids may be required to overcome the blockade — this carries risk of respiratory depression once the naltrexone wears off.

Allergic reactions: Hypersensitivity reactions, including anaphylaxis, have been reported. Standard emergency equipment should be available at the injection site.

When Vivitrol Is Preferred Over Oral Naltrexone

Vivitrol is the stronger clinical choice in the following situations:

Documented adherence concerns: If a patient has tried oral naltrexone and missed doses consistently, or if their history suggests daily medication adherence will be difficult, the structural adherence advantage of monthly injection is clinically meaningful.

Criminal justice and supervised treatment contexts: Drug courts, probation programs, and reentry settings frequently use Vivitrol because monthly injection provides verifiable, supervised medication delivery. A patient who receives an injection in front of a clinician is definitively adherent for that month in a way that cannot be confirmed with daily pills.

Patient preference for monthly dosing: Some patients find the monthly injection preferable to a daily reminder of their diagnosis. The reduced frequency of medication-related decisions can feel liberating. This is a legitimate patient-centered reason to choose Vivitrol.

Repeated failure of oral therapy due to missed doses: If a patient has relapsed specifically during periods of oral naltrexone non-adherence, switching to Vivitrol addresses the mechanism of failure directly.

Patients who prefer not to manage daily medications: People with complex medication regimens, unstable housing, or chaotic daily schedules may benefit from the simplicity of once-monthly treatment.

When Oral Naltrexone Is Preferred

Oral naltrexone (50mg daily) remains the appropriate first choice in many situations:

First-time AUD pharmacotherapy trial: For a patient who has never tried naltrexone, starting with the oral formulation allows assessment of tolerability and response before committing to the higher cost and irreversibility of the injection.

Cost sensitivity: At approximately $30/month for generic oral naltrexone versus approximately $1,500/month for Vivitrol, cost is a decisive factor for many patients and programs. When insurance coverage is uncertain or absent, oral naltrexone is far more accessible.

Patient preference for daily medication: Some patients prefer the sense of agency that comes with taking a daily pill. They want to be able to stop the medication quickly if needed. Oral naltrexone allows that flexibility; Vivitrol does not.

Needle phobia: A meaningful proportion of patients will decline injectable treatment due to fear of needles. This is a valid reason to use oral naltrexone, and it should be respected without judgment.

Dose flexibility: Oral naltrexone can be titrated, paused, or discontinued immediately. Vivitrol cannot. In patients whose clinical situation may change rapidly — including those with uncertain opioid use patterns — the flexibility of oral dosing is a safety advantage.

Liver function concerns: While both formulations carry hepatotoxicity warnings, the ability to immediately discontinue oral naltrexone if LFTs rise is an advantage over the depot formulation.

Cost and Insurance

Wholesale cost: Vivitrol costs approximately $1,500 per monthly injection at wholesale acquisition cost. With administration fees, the total monthly cost can exceed $1,600–$1,800 in many settings.

Oral naltrexone comparison: Generic oral naltrexone costs approximately $25–$40 per month. This cost difference — roughly 40-to-1 — is the central financial reality of choosing between these formulations.

Commercial insurance: Most commercial insurance plans cover Vivitrol, typically requiring prior authorization. The prior authorization process can take days to weeks and may require documentation of a diagnosis, previous treatment attempts, and clinical justification. Programs should have dedicated staff or workflows for managing prior authorization to avoid treatment delays.

Medicaid: Coverage varies significantly by state. Some state Medicaid programs cover Vivitrol with prior authorization; others have restrictions or require step therapy (trying oral naltrexone first). Program administrators should verify coverage for their specific state Medicaid formulary.

Medicare: Medicare Part D covers Vivitrol, subject to plan-specific formulary placement and cost-sharing.

Alkermes Patient Assistance Program: Alkermes, the manufacturer of Vivitrol, operates a patient assistance program for uninsured or underinsured patients who meet income eligibility criteria. Program administrators and prescribers should be familiar with the application process. Information is available through the manufacturer directly.

Criminal justice and grant funding: Many drug court and reentry programs access Vivitrol through state or federal grant funding (including SAMHSA grants), which can significantly reduce or eliminate patient cost. This funding landscape varies by jurisdiction and changes over time.

Vivitrol in Criminal Justice Settings

Vivitrol has been heavily adopted in drug courts, reentry programs, probation supervision, and pre-trial diversion programs. Understanding why — and the legitimate concerns this raises — is essential for anyone working in or navigating these systems.

Why Vivitrol is prevalent in criminal justice settings:

First, monthly injection provides verifiable adherence in a way that daily pills cannot. A drug court judge or probation officer can confirm that a participant received their injection; they cannot confirm that a participant took their pill each morning.

Second, and more controversially, agonist therapies are frequently unavailable in criminal justice settings. Methadone can only be dispensed through federally licensed opioid treatment programs (OTPs), which are not available in most jails, prisons, or community supervision offices. Buprenorphine, while more accessible, faces significant stigma and regulatory barriers in many criminal justice contexts. Vivitrol, as a non-controlled substance with no abuse potential, faces fewer institutional barriers. The result is that in many drug courts and reentry programs, Vivitrol is not chosen from a menu of options — it is the only option offered.

The controversy:

The concentration of Vivitrol in criminal justice settings, combined with the frequent absence of agonist alternatives, raises genuine ethical concerns about voluntary informed consent. When a person is told that their participation in a drug court program or their release from incarceration is contingent on receiving Vivitrol injections, the voluntariness of that consent is legitimately questionable. This concern is not hypothetical — it has been raised by patient advocates, addiction medicine specialists, and legal scholars.

The clinical concern that accompanies this is equally important: Vivitrol is not appropriate for everyone with OUD or AUD, and mandating it without individualized clinical assessment can result in patients receiving a medication that is not the best fit for their needs. For people with OUD in particular, the evidence base for methadone and buprenorphine is stronger than for naltrexone, and restricting access to those medications in favor of Vivitrol — even implicitly — may not serve patients' best interests.

What this means in practice:

• Patients in criminal justice settings have the right to know what medications are available to them, including agonist therapies, even if those therapies are not offered through the specific program
• Informed consent for Vivitrol should include honest discussion of alternatives
• Programs should document that consent was given voluntarily and that the patient understood their options
• Clinicians working in these settings should advocate for expanding access to the full range of evidence-based treatments

The panel's criminal justice specialist identified the absence of outcome data from criminal-justice-mandated versus voluntary Vivitrol use as one of the most consequential gaps in the current evidence base.

Missed Dose Schedule

If a monthly Vivitrol injection is missed or delayed, the following guidance applies:

Re-inject as soon as possible. There is no clinical reason to wait for a specific calendar date. The goal is to restore consistent receptor blockade as quickly as the patient can be seen.

No repeat opioid washout is required if the patient remained opioid-free during the gap between injections. The washout requirement applies to the initiation of naltrexone in an opioid-dependent person — not to re-dosing in a patient who has been maintained on Vivitrol and has not used opioids.

If opioid use occurred during the gap: Clinical assessment is required before re-injection. If the patient used opioids during the missed-dose period, they must complete a new washout period before the next injection. The same safety protocol as initial dosing applies.

Practical note for programs: Missed doses are a real operational challenge. Programs should have proactive outreach protocols — phone calls, text reminders, case manager contact — to minimize the gap between scheduled and actual injection dates. The longer the gap, the greater the risk of relapse and the greater the chance that opioid use during the gap will complicate re-initiation.

Evidence Gaps

Honest acknowledgment of what the evidence does not yet tell us is essential for responsible clinical decision-making. The expert panel identified the following as the most consequential gaps:

Long-term outcomes beyond 6–12 months: Most clinical trials of Vivitrol for AUD have follow-up periods of 6 months. What happens to patients at 1 year, 2 years, or 5 years — whether they continue medication, transition to oral naltrexone, achieve sustained remission, or relapse — is not well characterized in the published literature.

Comparative effectiveness versus oral naltrexone in real-world AUD populations: Head-to-head RCTs comparing Vivitrol to oral naltrexone in AUD populations are limited. Much of the adherence advantage argument rests on pharmacokinetic reasoning and real-world observational data rather than controlled trials with AUD-specific outcomes.

Outcomes in criminal-justice-mandated versus voluntary contexts: Whether Vivitrol produces the same outcomes when it is mandated as part of a legal agreement versus chosen voluntarily by a patient is an important and largely unanswered question. The ethical and clinical implications of this gap are significant.

Washout protocol optimization: The evidence base for specific washout durations, supervised initiation protocols, and bridge strategies for patients transitioning from opioid dependence to Vivitrol is thinner than clinicians need. This is particularly acute for patients approaching release from incarceration with a narrow, fixed window for treatment initiation.

Patient-reported experience data: Qualitative and mixed-methods research on what patients actually experience — the injection process, side effect burden, impact on daily life, reasons for discontinuation — is limited. This gap makes it harder to counsel patients accurately about what to expect.

Cost-effectiveness analyses: Rigorous cost-effectiveness comparisons between Vivitrol, oral naltrexone, and agonist therapies in AUD populations are limited, making it difficult to make evidence-based resource allocation decisions at the program or system level.

Summary: Key Points for Decision-Making

This article is intended as an educational resource and does not constitute medical advice. Clinical decisions regarding Vivitrol should be made in consultation with a qualified healthcare provider using current FDA prescribing information, ASAM guidelines, and peer-reviewed evidence.